Newsfileยท2025-11-23 00:00Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action related to alleged misleading statements and health risks associated with the company's glucose monitoring systems [2][3][6]. Group 1: Class Action Details - The class action pertains to investors who purchased DexCom securities between July 26, 2024, and September 17, 2025 [2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A lead plaintiff must file a motion with the court by December 29, 2025, to represent other class members [4]. Group 2: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [6]. - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues [6]. - The situation has led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [5]. - The firm was ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [5].